Diabetes-related biomarkers and treatment of diabetes-related conditions
OwnerWei Jiainventor
Life of this patent
Estimating the term…
Abstract
The present invention provides biomarkers useful for evaluating the risk that a subject will develop diabetes, monitoring such risk, identifying members of a population at risk of developing diabetes, calculating risk of a subject developing diabetes, advising subjects of risk for developing diabetes, providing diagnostic tests for identifying subjects at risk for developing diabetes or kits there for, and providing diagnostic tests for determining risk of a subject developing diabetes and kits there for. The present invention also provides compounds and methods for treating subjects.
Claims19
A method of determining the risk of a subject developing diabetes comprising:
- a. obtaining a biological sample from the subject;
- b. measuring the level of each biomarker of a panel in the sample, wherein the panel comprises at least one biomarker listed in FIG. 11, wherein said at least one biomarker comprises C16:0/C18:0 ratio;
- c. correlating the measured level with risk of developing diabetes;
- and
- d. determining the risk of the subject developing diabetes based on the correlation;
- and
- e. optionally, administering a treatment to the subject determined to be likely to develop diabetes.
A method of monitoring diabetes treatment of a subject comprising:
- a. obtaining a first biological sample from the subject and a second biological sample from the subject, wherein the first biological sample is obtained from the subject prior to the subject receiving a diabetes treatment and wherein the second biological sample is obtained from the subject following the subject receiving the diabetes treatment;
- b. measuring the level of at least one biomarker of FIG. 11 in the first sample and the second sample, wherein said at least one biomarker comprises C16:0/C18:0 ratio;
- c. comparing the measured level of the at least one biomarker in the first sample to the measured level of the at least one biomarker in the second sample;
- d. determining the efficacy of the treatment based on a deviation in the measured level of the at least one biomarker in the first sample relative to the measured level of the at least one biomarker in the second sample;
- and
- e. changing or discontinuing the treatment if the efficacy is determined to be below a threshold.
Dependencies are inferred from the claim text.